NP

Nicholas Plugis

Senior Principal at Flagship Pioneering

Cambridge, Massachusetts

Overview 

Nicholas Plugis is a Senior Principal at Flagship Pioneering in Cambridge, Massachusetts, with a background in molecular biology, cell biology, and biochemistry. With a Ph.D. from Stanford University, he has held key roles in multiple successful ventures, including Cellarity and Ring Therapeutics, showcasing his expertise in building and advising innovative biotech companies.

Work Experience 

  • Senior Principal

    2023 - Current

  • Principal

    2020 - 2023

  • Senior Associate

    2018 - 2020

  • Associate

    2017 - 2018

  • Consultant

    2016 - 2017

  • VentureLabs Fellow

    2016 - 2016

Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.

  • Advisor

    2022

  • Founding Team, Chief Innovation Officer

    2017 - 2022

    Cellarity develops novel medicines that are unreachable with traditional methods of drug discovery, completely revolutionizing the way drugs are created.

Cellarity is a therapeutics company that uses genomic technologies, data science, and AI to develop a new generation of therapies.

Raised $294,000,000.00 from Kyowa Kirin, Flagship Pioneering and Hanwha Impact Partners.

  • Advisor

    2022 - 2023

  • Founding Team

    2020 - 2022

    Abiologics, Inc. is a privately held, early-stage biotechnology company on a mission to make biology better through chemistry. We are pioneering the development of a transformational new class of medicines that is unlocked by novel synthetic and computational technologies.

  • Founding Team

    2021 - 2022

    Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else.

  • Founding Team

    2017 - 2019

Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.

Raised $490,000,000.00 from BlackRock, Invus, Flagship Pioneering, T. Rowe Price, Federated Kaufmann Fund, Longevity Vision Fund, Fidelity and CPP Investments.

  • Founding Team

    2017 - 2018

    Ring Therapeutics is revolutionizing the gene therapy and nucleic acid medicine space by harnessing the most abundant and diverse member of the human commensal virome, anelloviruses.

Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.

Raised $253,500,000.00 from Altitude Life Science Ventures, Flagship Pioneering, UPMC Enterprises, CJ Investment, Partners Investment, T. Rowe Price, Alexandria Venture Investments, Invus and Kyowa Kirin.

  • Vice President

    2015 - 2016

    Scientific and Market Advising in the Life Sciences

  • Engagement Manager

    2014 - 2015

  • Analyst

    2013 - 2014

  • Research Assistant

    2010 - 2011

    Department of Chemistry and Biochemistry, Laboratory of Dr. James Larrabee

  • Research Assistant

    2008 - 2009

    Departments of Chemistry and Radiology, Laboratory of Dr. Peter Caravan

Revolutionizing imaging for the advancement of science and medicine.

Articles About Nicholas

Relevant Websites